A U.K. group has investigated 31 biomarkers for their potential utility in the diagnosis and prognosis of multiple sclerosis (Kodosaki et al. J Neuroinflamm 2024;21:52). The biomarkers examined included neurofilament-light chain (NfL), glial fibrillary acidic protein (GFAP), chitinase-3-like-1 protein (CHi3L1), pro-and anti-inflammatory cytokines (e.g. IL-6, IL-10), chemokines (e.g. CXCL12), complement proteins (e.g. C3, C5) and proteins in other pathways relevant to MS (e.g. vitamin D binding protein). CSF and serum samples were obtained from 77 people being investigated for a demyelinating condition and 80 controls. Read More